Postępy Dermatologii i Alergologii

Full text

5/2026 vol. 43
Original paper

The efficacy of intraoperative onabotulinumtoxinA in preventing hypertrophic scarring: a randomised, double-blind, split-scar trial with biomarker analysis

Lei Zhao 1
,
Zhike Zhou 2
,
Zixin Zhou 3
,
Qinghua Li 1

  1. Department of Ultrasound, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China

  2. Department of Dermatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China

  3. Department of Plastic Surgery, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China

Adv Dermatol Allergol 2026; XLIII (5): 535-542

DOI: https://doi.org/10.5114/ada.2026.165985
Data publikacji online: 2026/10/22
Article file
PDiA The Efficacy.pdf
  1. Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 2006; 18: 396-402.
  2. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453: 314-21.
  3. Brown BC, McKenna SP, Siddhi K, et al. The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg 2008; 61: 1049-58.
  4. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-71.
  5. O’Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2013; 9: CD003826.
  6. Ogawa R, Akaishi S, Huang C, et al. Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and botulinum toxin A. Plast Reconstr Surg 2011; 128: 452e-3e.
  7. Wong VW, Akaishi S, Longaker MT, Gurtner GC. Pushing back: wound mechanotransduction in repair and regeneration. J Invest Dermatol 2011; 131: 2186-96.
  8. Xiao Z, Qu G. Effects of botulinum toxin type A on collagen deposition in hypertrophic scars. Aesthetic Plast Surg 2012; 36: 1010-5.
  9. Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A to improve scar outcome. Plast Reconstr Surg 2000; 105: 2128-33.
  10. Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2002; 18: 201-4.
  11. Wang L, Tai NZ, Fan ZH. Effect of botulinum toxin type A on the expression of substance P, calcitonin gene-related peptide, transforming growth factor beta-1 and alpha smooth muscle actin A in wound healing in rats. Zhonghua Zheng Xing Wai Ke Za Zhi 2009; 25: 50-3.
  12. Xiaoxue W, Xi C, Zhibo X. Effects of botulinum toxin type A on expression of genes in keloid fibroblasts. Aesth Surg J 2014; 34: 154-9.
  13. Kwan P, Hori K, Ding J, Tredget EE. The role of mast cells and interleukin-6 in the pathogenesis of hypertrophic scars. J Burn Care Res 2010; 31: 461-70.
  14. Sahinkanat T, Eroglu E, Basar H, et al. The effects of botulinum toxin A on wound healing in a rat model. J Plast Reconstr Aesthet Surg 2010; 63: 1194-9.
  15. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-b family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012; 2: 18-28.
  16. Ihn H. Pathogenesis of fibrosis: role of TGF-b and CTGF. Curr Opin Rheumatol 2002; 14: 681-5.
  17. Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 2014; 71: 1279-88.
  18. Scott JR, Muangman PR, Gibran NS. Making sense of hypertrophic scar: the role of inflammation. J Burn Care Res 2007; 28: 417-24.
  19. Li P, He QY, Luo CQ, Qian LY. The role of microRNAs in skin scarring. Adv Wound Care (New Rochelle) 2021; 10: 239-51.
  20. Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv Wound Care (New Rochelle) 2015; 4: 119-36.
  21. Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117: 1758-66.
  22. Tollefson TT, Senders CM, Sykes JM, Byorth PJ. Botulinum toxin to improve results in facelift surgery. Facial Plast Surg Clin North Am 2010; 18: 405-10.
  23. Chang CS, Wallace CG, Hsiao YC, et al. Botulinum toxin A to improve facial scarring in facelift patients: a randomized, double-blind, placebo-controlled, split-face study. Plast Reconstr Surg 2014; 133: 59-68.
  24. Ziade M, Domergue S, Batifol D, et al. Use of botulinum toxin type A to improve scar appearance: a review. J Cosmet Dermatol 2013; 12: 223-8.
  25. Kim YS, Lee HJ, Cho SH, et al. Early postoperative injection of botulinum toxin type A prevents hypertrophic scarring after upper blepharoplasty. Plast Reconstr Surg 2016; 138: 639e-45e.
  26. Gauglitz GG, Bureik D, Dombrowski Y, et al. Botulinum toxin A for the treatment of hypertrophic scars and keloids: a systematic review. Dermatol Surg 2012; 38: 1035-44.
  27. Elshahed AR, Elmanzalawy KS, Shehata H, Elsaie ML. Botulinum toxin A versus placebo for prevention of post-surgical scars: a systematic review and meta-analysis. J Cosmet Dermatol 2021; 20: 2410-9.
  28. Busche MN, Thraen AC, Gohritz A, et al. Split-skin graft: a versatile tool for scar reconstruction. Plast Reconstr Surg 2013; 132: 703e-11e.
  29. van der Kar AL, Corion LU, Smeulders MJ, et al. Reliable and feasible evaluation of linear scars by the Patient and Observer Scar Assessment Scale. Plast Reconstr Surg 2005; 116: 514-22.
  30. Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81: 1023-8.
  31. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.
  32. Carruthers A, Carruthers J. Botulinum toxin type A: history and current use. J Am Acad Dermatol 2005; 53: 282-92.
  33. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002; 359: 696-700.
  34. Gold MH. A controlled clinical trial of topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. J Am Acad Dermatol 1994; 30: 506-7.
  35. Krogstad AL, Lönnroth P, Larson G, Wallin BG. Increased interstitial histamine concentration in the psoriatic plaque. J Invest Dermatol 1997; 109: 632-5.
  36. Leask A, Abraham DJ. TGF-b signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
  37. Crawford J, Nygard K, Gan BS, O’Gorman DB. Periostin induces fibroblast proliferation and myofibroblast differentiation in Dupuytren’s disease. PLoS One 2015; 10: e0121205.
  38. Peters EM, Ericson ME, Hosoi J, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126: 1937-47.
  39. Ulrich D, Noah EM, von Heimburg D, Pallua N. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 2003; 111: 1417-23.
  40. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-97.
  41. Maurer B, Stanczyk J, Jüngel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010; 62: 1733-43.
  42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
  43. Draaijers LJ, Tempelman FR, Botman YA, et al. The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg 2004; 113: 1960-5.
  44. Nicholas RS, Falvey H, Lemonas P, et al. Patient-related barriers to a scar assessment tool: a qualitative study. Burns 2017; 43: 563-71.
  45. Sullivan T, Smith J, Kermode J, et al. Rating the burn scar. J Burn Care Rehabil 1990; 11: 256-60.
  46. Nedelec B, Correa JA, de Oliveira A, et al. Longitudinal burn scar quantification using the Cutometer. Burns 2016; 42: 1019-27.
  47. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146-68.
  48. Fong SS, Hung LK, Cheng JC. The cutometer and ultrasonography in the assessment of postburn hypertrophic scar. Burns 1997; 23: 591-6.
  49. Coté TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53: 407-15.
  50. Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty 2010; 10: e43.
  51. Li J, Li A, Zhai X, et al. The role of botulinum toxin type A in preventing hypertrophic scars: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98: e17637.
  52. Guo X, Song G, Zhang D, Jin X. Efficacy of botulinum toxin type A in improving scar quality and wound healing: a systematic review and meta-analysis of randomized controlled trials. Aesthet Surg J 2020; 40: NP428-39.
  53. Ogawa R, Okai K, Tokumura F, et al. The relationship between skin stretching/contraction and pathologic scarring: the important role of mechanical forces in keloid generation. Wound Repair Regen 2012; 20: 149-57.
  54. Verhaegen PD, van der Wal MB, Middelkoop E, van Zuijlen PP. Scar pliability: objective and subjective assessment. In: Textbook on Scar Management. Téot L, Mustoe TA, Middelkoop E, Gauglitz GG, eds. Springer 2020; 231-9.
  55. Lee BJ, Jeong JH, Wang SG, et al. Effect of botulinum toxin type A on a rat surgical wound model. Clin Exp Otorhinolaryngol 2009; 2: 24-9.
  56. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
  57. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999; 13: 1774-86.
  58. Oh SH, Lee Y, Seo YJ, et al. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg 2012; 38: 1689-94.
  59. Norris RA, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007; 101: 695-711.
  60. Scott JR, Murad S, Tahir H, et al. Substance P and the neurogenic inflammatory response in wound healing. Wound Repair Regen 2005; 13: 391-7.
  61. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785-93.
  62. Zhu Z, Ding J, Tredget EE. The molecular basis of hypertrophic scars. Burns Trauma 2016; 4: 2.
  63. Zhou R, Hu G, Liu J, et al. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog 2009; 5: e1000681.
  64. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-32.
  65. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J 2010; 277: 2015-21.
  66. Kim SH, Lee SJ, Lee JW, et al. Clinical trial to evaluate the efficacy of botulinum toxin type A injection for reducing scars in patients with forehead laceration. Arch Craniofac Surg 2019; 20: 291-7.
  67. Raslan EE, Bakhamees BH, Howsawi TA, et al. The efficacy of botulinum toxin type A (BTA) in the treatment of hypertrophic scars and keloids: a systematic review and meta-analysis of randomized controlled trials. Cureus 2024; 16: e71161.
  68. Byar DP, Piantadosi S. The use of the split-body design in clinical trials. Control Clin Trials 1985; 6: 172-82.
  69. Tyack Z, Simons M, Spinks A, Wasiak J. A systematic review of the quality of burn scar rating scales for clinical and research use. Burns 2012; 38: 6-18.
  70. Carruthers A, Carruthers J. Dose-finding studies of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 766-72.
  71. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 2010; 11: 183-99.
  72. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician 2009; 80: 253-60.
  73. Monstrey S, Middelkoop E, Vranckx JJ, et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg 2014; 67: 1017-25.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications